ArticleBrain and behavior2017
Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
Article in Brain and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Grey matter changes on brain MRI in subjective cognitive decline: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Effects of Tai Chi on Patients with Mild Cognitive Impairment: A Systematic Review and Meta-analysis of Randomized Controlled Trials.BioMed research international · 2021Pooled it
- Inside and outside the body space: a study on environmental knowledge, interoceptive and functional body representations in the prodromal stage of dementia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- EEG-based biomarker for the identification of mild cognitive impairment via coherency analysis and iterative dynamic time warping.Scientific reports · 2026Article
- Prevalence and associated factors of subjective cognitive decline (SCD Plus): a cross-sectional analysis of three population-based European cohorts.Alzheimer's research & therapy · 2026Article
- Mild cognitive impairment cases affect the predictive power of Alzheimer's disease diagnostic models using routine clinical variables.npj aging · 2026Article
- Review
- Neuropsychiatric and neural correlates of subjective cognitive complaint.Aging clinical and experimental research · 2026Article
- Harvesting Health: Phytochemicals in Cognitive Impairment Therapy.Central nervous system agents in medicinal chemistry · 2025Review
- Mild cognitive impairment and neuropsychological examination.Frontiers in psychology · 2025Review
- In vivo PET of synaptic density as potential diagnostic marker for cognitive disorders: prospective comparison with current imaging markers for neuronal dysfunction and relation to symptomatology - study protocol.BMC medical imaging · 2024Article
- Do Associations Between Vascular Risk and Mild Cognitive Impairment Vary by Race?Journal of aging and health · 2023Article
- Neurocognitive Operations Underlying Working Memory Abilities: An Analysis of Latency and Time-Based Parameters.Journal of Alzheimer's disease : JAD · 2023Article
- Abnormal Dynamic Functional Networks in Subjective Cognitive Decline and Alzheimer's Disease.Frontiers in computational neuroscience · 2022Article
- Decreased Cortical Thickness and Local Gyrification in Individuals with Subjective Cognitive Impairment.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Risk factors for subjective cognitive decline: the CABLE study.Translational psychiatry · 2021Article
- Altered Functional Connectivity of the Basal Nucleus of Meynert in Subjective Cognitive Impairment, Early Mild Cognitive Impairment, and Late Mild Cognitive Impairment.Frontiers in aging neuroscience · 2021Article
- Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Role of phytochemicals as nutraceuticals for cognitive functions affected in ageing.British journal of pharmacology · 2020Review
- A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders.Frontiers in neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPreclinical Alzheimers disease (AD) patients may or may not show cognitive impairment on testing. AD biomarkers are central to the identification of those at low, intermediate, or high risk of later dementia due to AD. We investigated biomarker distribution in those identified as subjective cognitive decline (SCD), amnestic (aMCI), and nonamnestic (naMCI) mild cognitive impairment (MCI) subtypes. In addition, the clinical groups were compared with controls on downstream neuroimaging markers. MATERIALS AND
methodsCerebrospinal fluid (CSF) amyloid-β42 (A β42) and total tau (t-tau), phosphorylated tau (p-tau), fluorodeoxyglucose (FDG), positron-emission tomography (PET), and MRI neuroimaging measures were collected from 116 memory clinic patients. They were characterized as SCD, aMCI, and naMCI according to comprehensive neuropsychological criteria. ANOVAs were used to assess differences when biomarkers were treated as continuous variables and chi square analyses were used to assess group differences in distribution of biomarkers.
resultsWe did not find any between group differences in Aβ42, nor in p-tau, but we observed elevated t-tau in aMCI and SCD relative to the naMCI group. Significantly lower cortical glucose metabolism (as measured by FDG PET) was found in aMCI relative to SCD and controls, and there was a trend for lower metabolism in naMCI. Significant thinner entorhinal cortex (ERC) was found in aMCI and SCD. As expected biomarkers were significantly more frequently pathological in aMCI than in naMCI and SCD, whereas the naMCI and SCD groups displayed similar pathological biomarker burden.
conclusionsaMCI cases show the most pathologic biomarker burden. Interestingly naMCI and SCD subjects show similar levels of pathological biomarkers albeit the former displayed neuropsychological deficits. That the latter group may represent a risk group is supported by our observation of both elevated CSF tau and thinner ERC relative to controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.